Athersys to reshape trial for cell therapy in heart attack after regaining rights
This article was originally published in Scrip
Executive Summary
Athersys, a Cleveland, Ohio-based company working on non-embryonic stem cell preparations, has regained the exclusive rights to its Multistem stem cell therapy for the cardiovascular field through the mutual termination of its collaboration with struggling Canadian company Angiotech Pharmaceuticals.